Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA)

被引：0
|
作者：
Glaspy, J
Berg, R
Tomita, D
Rossi, G
Vadhan-Raj, S
机构：
[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：760S / 760S
页数：1
相关论文
共 50 条
  • [21] Investigation of epoetin alfa (EPO) 80,000 units (U) every 4 weeks (Q4W) vs. 40,000 U every 2 weeks (Q2W) in patients with cancer not receiving chemotherapy (CT) or radiation therapy (RT): Final results
    Shasha, Daniel
    Dawkins, Fitzroy
    Luo, Donghan
    Wilhelm, Francois E.
    Kamin, Marc
    BLOOD, 2007, 110 (11) : 10B - 10B
  • [22] Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 study group trial
    Glaspy, John
    Vadhan-Raj, Saroj
    Patel, Ravi
    Bosserman, Linda
    Hu, Eddie
    Lloyd, Richard E.
    Boccia, Ralph V.
    Tomita, Dianne
    Rossi, Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2290 - 2297
  • [23] A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer
    Schwartzberg, LS
    Yee, LK
    Senecal, FM
    Charu, V
    Tomita, D
    Wallace, J
    Rossi, G
    ONCOLOGIST, 2004, 9 (06): : 696 - 707
  • [24] A multicenter study to assess the effects of darbepoetin alfa 200 mcg every 2 weeks (Q2W) in patients with nonmyeloid malignancies receiving chemotherapy: Early results of the SURPASS study.
    Gabrilove, J
    Crawford, J
    Swan, F
    Mendes, E
    Tomita, D
    Colowick, A
    BLOOD, 2003, 102 (11) : 19B - 19B
  • [25] RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF DARBEPOETIN ALFA (DA) ADMINISTERED EVERY THREE WEEKS (Q3W) IN PATIENTS WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)
    Suzuki, Y.
    Tokuda, Y.
    Okamoto, R.
    Nakagawa, K.
    Ando, K.
    Iwata, H.
    Tobinai, K.
    Tanigawara, Y.
    Hotta, T.
    Saijo, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 277 - 277
  • [26] Weekly epoetin alfa (QW) provides similar hematologic outcomes to front-loading (FL) darbepoetin alfa regimens and better outcomes compared to darbepoetin alfa (Q2W) in patients with chemotherapy-related anemia.
    Duh, MS
    Lefebvre, P
    Dector, AJ
    Watson, SH
    McKenzie, SR
    Piech, CT
    BLOOD, 2003, 102 (11) : 511B - 512B
  • [27] DARBEPOETIN ALFA (DA) 500MCG OR 300MCG ONCE EVERY THREE WEEKS (Q3W) WITH OR WITHOUT IRON IN PATIENTS (PTS) WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)
    Auerbach, Michael
    Silberstein, Peter T.
    Webb, R. Timothy
    Averyanova, Svetlana
    Ciuleanu, Tudor-Eliade
    Cam, Linh
    Shao, James
    Lillie, Tom
    ANNALS OF ONCOLOGY, 2008, 19 : 3 - 3
  • [28] Initiating epoetin alfa (EPO) 120,000 U every three weeks (Q3W) in pts with chemotherapy (CT)-induced anemia (CIA)
    Glaspy, J.
    Charu, V.
    Moyo, V.
    Kamin, M.
    Wilhelm, F. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: Final results.
    Gregory, SA
    Xie, J
    Woodman, RC
    BLOOD, 2005, 106 (11) : 21B - 21B
  • [30] A phase 2, randomized, open-label study to assess the efficacy of extended dose schedule administration of darbepoetin alfa (DA) in cancer patients (pts) with chemotherapy-induced anemia (CIA).
    Schwartzberg, Lee
    Rearden, Timothy
    Yee, Lorrin
    Mirtsching, Barry
    Charu, Veena
    Lam, Hung
    Lillie, Tom
    Burkes, Ronald
    Silberstein, Peter
    BLOOD, 2006, 108 (11) : 382A - 383A
12345